SRR934943
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 44.74375821287779
- age_years
- 65
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.564
- INTERFERON_ALPHA_RESPONSE+0.549
- ALLOGRAFT_REJECTION+0.504
- IL6_JAK_STAT3_SIGNALING+0.482
- TGF_BETA_SIGNALING+0.397
- ANGIOGENESIS+0.333
- NOTCH_SIGNALING+0.329
- IL2_STAT5_SIGNALING+0.328
- INFLAMMATORY_RESPONSE+0.321
- TNFA_SIGNALING_VIA_NFKB+0.293
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.472
- KRAS_SIGNALING_DN-0.270
- SPERMATOGENESIS-0.258
- OXIDATIVE_PHOSPHORYLATION-0.229
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
- ESTROGEN_RESPONSE_LATE-0.096
- MYOGENESIS-0.081
- HEDGEHOG_SIGNALING-0.074
- XENOBIOTIC_METABOLISM-0.074
- ESTROGEN_RESPONSE_EARLY-0.059
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.916 |
| 2 | SRR934864 | — | — | 0.903 |
| 3 | SRR934753 | — | — | 0.899 |
| 4 | BF513557-1518-4843-9F62-837B557D4CAB | — | — | 0.899 |
| 5 | SRR934862 | — | — | 0.895 |
| 6 | SRR934745 | — | — | 0.893 |
| 7 | SRR934737 | — | — | 0.888 |
| 8 | C1CCE12B-8892-49AB-8DF2-E5E280DEAE32 | — | — | 0.886 |
| 9 | SRR934741 | — | — | 0.884 |
| 10 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.564 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.549 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.504 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.482 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.397 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.333 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.329 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.328 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.321 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.293 | Inavolisib | — uncovered |
| APOPTOSIS | 0.286 | Idelalisib | — uncovered |
| COMPLEMENT | 0.265 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.258 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.244 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.238 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.223 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.212 | Inavolisib | — uncovered |
| COAGULATION | 0.191 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.187 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.177 | Inavolisib | — uncovered |